IKI. I. Kozan

I. I. Kozan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. I. Kozan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Sergiy Fedorov

    Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

    3 shared publications
  • Nataliia Kozan

    Івано-Франківський національний медичний університет, кафедра судової медицини, медичного та фармацевтичного права, м. Івано-Франківськ, Україна

    1 shared publication
  • Serhii Herashchenko

    Івано-Франківський національний медичний університет

    1 shared publication

Latest Publications

  • Open Access

    ВПЛИВ ДОДАВАННЯ ЕМПАГЛІФЛОЗИНУ ДО СТАНДАРТНОЇ ТЕРАПІЇ НА ЕХОКАРДІОГРАФІЧНІ ПОКАЗНИКИ ТА БІОМАРКЕРИ У ПАЦІЄНТІВ З ІНФАРКТОМ МІОКАРДА ТА ЗНИЖЕНОЮ ФРАКЦІЄЮ ВИКИДУ ЛІВОГО ШЛУНОЧКА

    by І. І. Козань, С. В. Федоров

    The aim of the study was to assess changes in echocardiographic parameters together with biomarkers of myocardial injury, hemodynamic stress, systemic inflammation and fibrosis in patients with reduced left ventricular ejection fraction after myocardial infarction. The investigation was performed at the Feofaniya Clinical Hospital and included patients with left ventricular ejection fraction below 40 % who were assigned either to guideline-based standard therapy or to standard treatment supplemented with empagliflozin. Before and after treatment, left ventricular ejection fraction, global longitudinal strain, indices of diastolic function, left atrial volume index, relative wall thickness and left ventricular myocardial mass index were evaluated, along with serum levels of hsCRP, NT-proBNP, hsTroponin I, GDF-15 and galectin-3, as well as integrated inflammatory indices NLR, PLR, SII, SIRI and AISI. Baseline clinical and anamnestic characteristics were generally comparable between groups, with the exception of a higher rate of uncontrolled hypertension in the empagliflozin group. After treatment, patients who received empagliflozin demonstrated a more pronounced improvement in left ventricular systolic performance and myocardial deformation, with significantly better post-treatment values and greater relative changes in ejection fraction and global longitudinal strain. A more favorable tendency was also observed for diastolic function and structural remodeling parameters. In addition, the empagliflozin group showed a larger reduction in NT-proBNP, hsTroponin I, hsCRP and GDF-15, as well as a more substantial decline in integrated inflammatory indices, particularly NLR, SII, SIRI and AISI. These findings suggest that the addition of empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction below 41 % may positively influence early post-infarction myocardial remodeling, attenuate inflammatory activation and reduce hemodynamic stress. The results support the view that empagliflozin may be considered a promising component of early cardiometabolic management in this high-risk category of patients, although larger prospective studies with longer follow-up are required to confirm its influence on hard clinical outcomes. In patients hospitalized with myocardial infarction and LVEF ≤40 %, the addition of empagliflozin to standard therapy was associated with a more pronounced improvement in left ventricular systolic function, manifested by significantly better changes in LVEF and GLS. Against the background of empagliflozin therapy, a more favorable dynamic of hemodynamic load and myocardial injury markers was observed, particularly NT-proBNP and hsTroponin I, as well as a more substantial reduction in hsCRP. The inclusion of empagliflozin in the treatment regimen was accompanied by a more pronounced decrease in the integrated inflammatory indices NLR, SII, SIRI, and AISI, indicating a potential beneficial effect of the drug on the systemic immune-inflammatory response in the early post-infarction period. The greater reduction in GDF-15 and the trend toward a more marked decrease in galectin-3 in the combination therapy group suggest a possible favorable effect of empagliflozin on post-infarction remodeling and myocardial fibrosis.

  • Open Access

    Effect of adding empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction >40 %: echocardiographic and biomarker changes

    by I.I. Kozan, S.V. Fedorov

    Objective. To evaluate the effect of adding empagliflozin to standard therapy in patients admitted with myocardial infarction with concomitant heart failure with left ventricular ejection fraction >40 % (mid-range and preserved) on echocardiographic parameters and biomarkers reflecting myocardial injury, hemodynamic stress, systemic inflammation, and fibrosis.Materials and methods. The study included patients hospitalized for myocardial infarction at Feofaniya Clinical Hospital. Guideline-directed medical therapy (GDMT) group consisted of patients with myocardial infarction and heart failure with mid-range ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF) who received standard treatment. GDMT + E (GDMT + empagliflozin) group included patients with myocardial infarction and HFmrEF/HFpEF who received standard treatment plus empagliflozin. Baseline clinical and anamnestic characteristics were assessed before treatment. Echocardiography included left ventricular ejection fraction, global longitudinal strain, E/e′, deceleration time, left atrial volume index, relative wall thickness, and left ventricular mass index. Laboratory assessment included high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, and inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation). Quantitative data are presented as mean ± standard deviation. Student’s t-test was used for independent-group comparisons, paired t-test for within-group comparisons, and χ² test for qualitative variables. Differences were considered significant at p<0.05.Results. At baseline, GDMT and GDMT + E groups were comparable in age, sex, infarction presentation, Killip class, extent of coronary involvement, major complaints, and comorbidities. After treatment, patients receiving empagliflozin demonstrated more pronounced improvement in systolic function and myocardial deformation. Left ventricular ejection fraction increased from 48.0 ± 4.1 % to 51.8 ± 4.0 % in GDMT + E group versus from 47.8 ± 4.2 % to 49.9 ± 4.2 % in GDMT group, with a significant between-group difference after treatment (p=0.049). Global longitudinal strain also improved more markedly in GDMT + E group (from 14.2 ± 1.9 % to 16.0 ± 1.9 %) than in GDMT group (from 14.0 ± 2.0 % to 15.1 ± 1.9 %; p=0.045). More favorable changes were also observed for high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation, with significantly lower post-treatment values in the empagliflozin group for most of these markers. Conclusions. In patients admitted with myocardial infarction and HFmrEF/HFpEF, the addition of empagliflozin to standard therapy was associated with a more favorable recovery of left ventricular systolic function, better myocardial deformation indices, and a more pronounced reduction in biomarkers of inflammation, myocardial stress, injury, and fibrosis. These findings support the potential role of empagliflozin as an adjunctive cardiometabolic strategy in post-infarction patients and warrants follow-up studies of potential class-effect of sodium-glucose cotransporter 2inhibitors.

  • Open Access

    Empagliflozin attenuates post-injury myocardial remodeling in a rat isoproterenol model: a morphological and morphometric study

    by I. I. Kozan, S. V. Fedorov, N. M. Kozan, A. S. Herashcenko

    Adverse post-myocardial infarction remodeling is a key pathway toward chronic heart failure. While sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure, evidence on their structural effects when therapy is initiated after the acute injury phase remains limited. Study aim – to evaluate whether delayed initiation of empagliflozin attenuates histological remodeling features and reduces morphometric indices of cardiomyocyte hypertrophy in rats with isoproterenol-induced myocardial injury. Sixty male outbred white rats (200-250 g) were allocated to three groups (n=20 each): intact control, isoproterenol (ISO) + placebo, and ISO + empagliflozin. Myocardial injury was induced by ISO (85 mg/kg/day, subcutaneously, on days 0 and 1). From day 14, animals received empagliflozin (10 mg/kg/day by oral gavage) or vehicle for 30 days. Hearts were harvested on day 44. Left-ventricular sections were obtained from subendocardial, intramural, and subepicardial layers and stained with hematoxylin-eosin and Masson’s trichrome. Digital morphometry quantified cardiomyocyte and nuclear area. Statistical analysis was conducted using the IBM SPSS 26.0 software (IBM, USA). It was established that ISO caused microvascular congestion, interstitial edema, cardiomyocyte disarray, and increased collagen deposition on Masson’s staining. Delayed empagliflozin reduced the qualitative severity of injury and attenuated hypertrophic morphometry. Cardiomyocyte area was higher in ISO + placebo than in control (342.8±12.5 μm² vs 223.2±8.4 μm²; p<0.01) and decreased in ISO + empagliflozin (287.4±8.3 μm²; p<0.05 vs ISO + placebo), while remaining above control. Nuclear area followed a similar pattern (36.95±1.07 μm² vs 20.73±0.54 μm² in ISO + placebo and 26.81±0.65 μm² with empagliflozin). Acquired data suggests that delayed empagliflozin use after the experimental myocardial damage partially alleviates structural remodelling and morphometric signs of cardiomyocyte hypertrophy.